Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (THE PALISADE STUDY)

Intervention/treatment:
AR101
Medical condition:
ALLERGIES PEANUT
Protocol code:
ARC003
Control number:
189441
Status:
Closed
Approved:
December 10, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02635776
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
4 Years to 55 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Director of Regulatory Affairs
Organization
Aimmune Therapeutics, Inc.
Phone:
650-409-5164
Sponsor
AIMMUNE THERAPEUTICS, INC

Locations

Ontario

Cheema Research, Inc.
Mississauga, Ontario, L5A 3V4
Gordon Sussman Clinical Research, Inc.
Toronto, Ontario, M4V 1R2
Ohayon
Hamilton, Ontario, L8S 1G5
Ottawa Allergy Research Corp
Ottawa, Ontario, K1G 6C6

Quebec

Montreal Children's Hospital
Montreal, Quebec, H4A3J1

Results

See the results from the trial NCT02635776. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?